Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

被引：4
|
作者：
Planchard, D. [1 ]
Brahmer, J. R. [2 ]
Yang, J. C-H. [3 ]
Kim, H. R. [4 ]
Li, R. K. [5 ]
Han, J-Y. [6 ]
Cortinovis, D. L. [7 ]
Runglodvatana, Y. [8 ]
Nakajima, E. [9 ]
Ragone, A. [10 ]
Winter, M. [11 ]
Gustavson, M. [12 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Johns Hopkins Kimmel Canc Ctr, Thorac Oncol Program, Baltimore, MD USA
[3] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[4] Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med, Seoul, South Korea
[5] St Lukes Med Ctr Quezon City, Dept Med Oncol, Quezon City, Philippines
[6] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[7] Fondazione IRCCS San Gerardo dei Tintori, SC Oncol Med, Monza, Italy
[8] Navamindradhiraj Univ, Div Med Oncol, Vajira Hosp, Fac Med, Bangkok, Thailand
[9] AstraZeneca, Late Dev Oncol, R&D, Gaithersburg, MD USA
[10] AstraZe neca, Late Dev Oncol, R&D, Mississauga, ON, Canada
[11] AstraZeneca, Data Sci & Quantitat Biol, Cambridge, England
[12] AstraZeneca, Translat Med, Oncol R&D, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1507TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
  • [42] A multicenter phase II study of induction chemotherapy with gemcitabine and carboplatin in patients (pts) with locally advanced non-small cell lung cancer (NSCLC)
    Aerts, J
    van Klaveren, R
    Surmont, V
    Senan, S
    Tan, Y
    Vernhout, R
    van Wijhe, G
    Verhoeven, G
    Hoogsteden, H
    van Meerbeeck, J
    LUNG CANCER, 2005, 49 : S164 - S164
  • [43] CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY REGIMENS IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) USING GERMAN REGISTRY DATA
    Haas, J. S.
    Meise, D.
    Ogbonnaya, A.
    Braun, S.
    Eaddy, M.
    Daessler, K.
    Sandner, R.
    Binninger, A.
    Jaenicke, M.
    Chiabudini, M.
    Marschner, N.
    VALUE IN HEALTH, 2017, 20 (09) : A416 - A417
  • [44] A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
    Cejalvo, Juan-Miguel
    Jacob, Wolfgang
    Kanonnikoff, Tania Fleitas
    Felip, Enriqueta
    Navarro Mendivil, Alejandro
    Martinez Garcia, Maria
    Garcia, Alvaro Taus
    Leighl, Natasha
    Lassen, Ulrik
    Mau-Soerensen, Morten
    Adessi, Celine
    Michielin, Francesca
    James, Ian
    Ceppi, Maurizio
    Hasmann, Max
    Weisser, Martin
    Cervantes, Andres
    ESMO OPEN, 2019, 4 (04)
  • [45] A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
    Clement-Duchene, Christelle
    Krupitskaya, Yelena
    Ganjoo, Kristen
    Lavori, Philip
    McMillan, Alex
    Kumar, Atul
    Zhao, Gary
    Padda, Sukhmani
    Zhou, Lisa
    San Pedro-Salcedo, Melanie
    Colevas, A. Dimitrios
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1821 - 1825
  • [46] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
    Steuer, Conor Ernst
    Hayashi, Hidetoshi
    Su, Wu-Chou
    Nishio, Makoto
    Johnson, Melissa Lynne
    Kim, Dong-Wan
    Koczywas, Marianna
    Felip, Enriqueta
    Gold, Kathryn A.
    Murakami, Haruyasu
    Baik, Christina S.
    Kim, Sang-We
    Smit, Egbert F.
    Gigantone, Mark
    Kim, Ben
    Fan, Pang-Dian
    Qi, Zhenhao
    Wu, Elaine Y.
    Sternberg, David W.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] EVALUATION OF SURVIVAL OUTCOMES IN SELECT FIRST-LINE TREATMENT REGIMENS FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Bhor, M.
    Winfree, K. B.
    Sail, K.
    Zagar, A.
    Pohl, G.
    Dhanda, R.
    VALUE IN HEALTH, 2013, 16 (03) : A1 - A1
  • [48] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
    Johnson, M. L.
    Steuer, C. E.
    Hayashi, H.
    Su, W. -C.
    Nishio, M.
    Kim, D. -W.
    Koczywas, M.
    Felip, E.
    Gold, K. A.
    Murakami, H.
    Baik, C. S.
    Kim, S. -W.
    Smit, E. F.
    Gigantone, M.
    Kim, B.
    Fan, P. -D.
    Qi, Z.
    Wu, E. Y.
    Sternberg, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
  • [49] EFFICACY AND SAFETY OF CISPLATIN/PEMETREXED AS FIRST-LINE TREATMENT FOR JAPANESE PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Yamaguchi, Teppei
    Nakanishi, Toru
    Hayashi, Masamichi
    Isogai, Sumito
    Hoshino, Tami
    Mieno, Yuki
    Uozu, Sakurako
    Morishita, Mariko
    Okamura, Takuya
    Takeyama, Tomoko
    Minezawa, Tomoyuki
    Morikawa, Sayako
    Niwa, Yoshikazu
    Okazawa, Mitsushi
    Imaizumi, Kazuyoshi
    RESPIROLOGY, 2013, 18 : 83 - 83
  • [50] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345